araag2/HINT huggingface dataset:
Clinical trial NCT01470456 (phase 2, status: completed)
Conditions: diffuse large b-cell lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: sar3419, rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion criteria:

          -  Histological diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL)

          -  Relapsed or refractory after at least one standard treatment including rituximab

          -  CD19 and CD20 positive disease

        Exclusion criteria:

          -  No bi-dimensionally measurable lesion by CT scan (defined as presence of at least one
             tumor mass measuring >1.5 x 1.5 cm)

          -  The above information is not intended to contain all considerations relevant to a
             patient's potential participation in a clinical trial.
Clinical trial NCT00254137 (phase 2, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: capecitabine, irinotecan, oxaliplatin, cetuximab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed metastatic colorectal cancer.

          -  EGF-receptor testing.

          -  No prior chemotherapy for colorectal cancer (except adjuvant chemotherapy with an
             interval ³ 6 months).

          -  No prior therapy with topoisomerase-1 inhibitors, no prior therapy directed against
             the EGF-pathway.

          -  No prior surgery (except diagnostic biopsy) or radiation therapy 4 weeks before start
             of study treatment.

          -  Measurable disease (diameter ³ 20mm, diameter ³ 10mm with spiral-CT).

          -  Male and female patients ³ 18 years, £ 75 years. Karnofsky PS ³ 70%. Life expectancy ³
             3 months. Effective contraception if risk of conception exists.

          -  Adequate bone marrow, liver and renal function (leucocytes ³3.000/µl, neutrophils
             ³1.500/µl, platelets ³100.000/µl, hemoglobin ³9g/dl, bilirubin £1,5x ULN, ASAT and
             ALAT £3x ULN (£5x ULN with liver metastasis), serum creatinine £1,5x ULN).

          -  Written informed consent.

        Exclusion Criteria:

          -  Concurrent treatment of colorectal cancer (except study medication).

          -  EGF-receptor testing not possible.

          -  Known DPD-deficiency (no particular screening necessary). Known
             Gilbert-Meulengracht-Syndrome (no particular screening necessary).

          -  Known or expected contraindication against study medication.

          -  Participation in other studies during 30 days before study entry.

          -  Prior myocardial infarction, severe renal insufficiency (creatinine clearance
             £30ml/min).

          -  Previous malignancy (except colorectal cancer, history of basal cell carcinoma of skin
             or pre-invasive carcinoma of the cervix with adequate treatment and no sign of disease
             during 5 years).

          -  Known or suspected cerebral metastasis.

          -  History of inflammatory bowel disease. Symptomatic peritoneal carcinomatosis.

          -  Drug or alcohol abuse. Lack of adequate legal capacity.

          -  Breast-feeding or pregnant women.

          -  Concurrent medication with Sorivudine and analoga, anticoagulation with Cumarine or
             derivatives.
Clinical trial NCT01735617 (phase 2, status: completed)
Conditions: endocrine disease, adrenal insufficiency, congenital adrenal hyperplasia
ICD codes: N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1, N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: hydrocortisone modified release capsules
SMILES: [O-][N+]1=C(S)C=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Known CAH due to 21-hydroxylase deficiency (classic CAH) based on hormonal and genetic
             testing currently treated with hydrocortisone, prednisone, prednisolone or
             dexamethasone on a stable dosage for a minimum of 3 months.

          2. Male or female patients aged 18 and above.

          3. Provision of signed written informed consent.

          4. Good general health.

          5. Females of childbearing potential must have a negative pregnancy test initially and at
             all visits. Females who are engaging in sexual intercourse must be using a medically
             acceptable method of contraception (as defined in the protocol, section 10.5).

          6. Plasma renin activity must be within the clinically acceptable range at screening
             (less than 1.5 times upper normal range).

        Exclusion Criteria:

          1. Co-morbid condition requiring daily administration of a medication that induces
             hepatic enzymes or interferes with the metabolism of glucocorticoids.

          2. Clinical or biochemical evidence of hepatic or renal disease. Creatinine above the
             normal range or elevated liver function tests (ALT or AST) > 2 times the upper limits
             of normal.

          3. Females who are pregnant or lactating.

          4. Women taking an estrogen-containing oral contraceptive pill and who have taken it
             within 6 weeks of recruitment.

          5. Patients taking spironolactone.

          6. Patients on inhaled or oral steroids apart from treatment for CAH.

          7. Patients with any other significant medical or psychiatric conditions that in the
             opinion of the Investigator would preclude participation in the trial.

          8. Participation in another clinical trial of an investigational or licensed drug or
             device within the 3 months prior to inclusion in this study.

          9. Patients with history of bilateral adrenalectomy.
Clinical trial NCT01016912 (phase 2, status: completed)
Conditions: hepatitis c infection
ICD codes: B17.0
Drugs: bms-790052, bms-790052, placebo, peginterferon alfa-2b, ribavirin
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CCCNC(N)=N)C(O)=O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Patients chronically infected with hepatitis C virus (HCV) genotype 1

          -  HCV RNA viral load ≥10*5* IU/mL at screening

          -  Naïve or nonresponsive to the current standard of care

        Key Exclusion Criteria:

          -  Cirrhosis

          -  Hepatocellular carcinoma

          -  Coinfection with hepatitis B virus, HIV-1 or HIV-2
Clinical trial NCT00221754 (phase 2, status: completed)
Conditions: hiv infection, hypercholesterolemia
ICD codes: Z21, E78.01, E78.00, Z83.42
Drugs: pravastatin (drug)
SMILES: [H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC
Eligibility criteria:

        Inclusion Criteria:

          -  confirmed HIV-1 infection (ELISA confirmed by Western-Blot test) ;

          -  Age above 18 years

          -  Stable antiretroviral therapy including at least one PI for >= 3 months,

          -  Plasma HIV-RNA level of < 50 copies/mL for >= 3 months before randomization,

          -  Total cholesterol > = 5.5 mmol/L with LDL-cholesterol > = 3.4 mmol/L on fasting status
             after three months of standardized dietary advice,

          -  signed informed consent

        Exclusion Criteria:

          -  Current AIDS event or infectious disease

          -  Tumoral, inflammatory, muscle diseases; kidney or hepatic failure

          -  Psychiatric conditions

          -  Biological elevated muscular enzymes

          -  Chronic alcohol consumption

          -  Pregnancy
Clinical trial NCT00533429 (phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: enzastaurin, pemetrexed, carboplatin, bevacizumab, placebo
SMILES: CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  they or their legal representative must have signed an informed consent document for
             clinical research

          -  have laboratory confirmed diagnosis of advanced, nonsquamous cell NSCLC (Stage IIIB or
             IV disease) which is not curable

          -  have not received any prior systemic chemotherapy, immunotherapy, targeted therapy, or
             biological therapy for advanced NSCLC, prior radiation therapy is allowed to less than
             25% of the bone marrow

          -  have measurable disease

          -  have adequate organ function and estimated life expectancy of 12 weeks

        Exclusion Criteria:

          -  have known CNS disease; major surgery within 28 days; minor surgery within 7 days;
             serious concommitant systemic disorder; serious cardiac condition; have a serious,
             nonhealing wound, ulcer, or bone fracture

          -  have received treatment within the last 30 days with any drug that has not received
             regulatory approval for any indication at the time of study entry

          -  have previously received treatment with enzastaurin, pemetrexed, or bevacizumab

          -  are pregnant or breast-feeding

          -  are unable to swallow tablets
Clinical trial NCT01811576 (phase 2, status: completed)
Conditions: growth hormone deficiency
ICD codes: D81.810, E53.0, E53.1, E61.0, E61.1, E61.2, E61.3
Drugs: tv-1106, recombinant human growth hormone
SMILES: O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient agrees to provide written informed consent and to comply with the study
             protocol after reading the informed consent and discussing the study with the
             investigator.

          -  Males and females between 23 and 65 years of age must have a confirmed diagnosis of
             adult GHD, either adult onset (AO) GHD due to hypothalamic-pituitary disease or
             childhood onset (CO) GHD that is either idiopathic or due to hypothalamic-pituitary
             disease or due to genetic causes.

          -  Diagnosis of GH deficiency must be confirmed by documented (medical records)
             diagnostic testing.

          -  Patients should have been treated with a stable dose of daily rhGH for at least 3
             months prior to screening.

          -  Other criteria apply.

        Exclusion Criteria:

          -  Patients with history or clinical evidence of active or chronic diseases that could
             confound results of the study or put the subject at undue risk as determined by the
             investigator.

          -  Patients with known active malignancy

          -  Patients with history of malignancy other than intracranial tumor causing GHD
             (excluding surgically cured basal cell or squamous cell cancer of the skin with
             documented 6 month remission)

          -  Patients with evidence of pituitary adenoma or other intracranial tumor within 12
             months of enrollment, which is on day 0 (baseline, Visit 3)

          -  Patients without magnetic resonance imaging (MRI) or computerized tomography (CT) data
             to document tumor stability within the 12 months prior to enrollment, which is on day
             0 (baseline, Visit 3)

          -  Presence of Prader-Willi syndrome, Turner's syndrome, untreated adrenal insufficiency,
             active acromegaly in the past 5 years, or active Cushing's syndrome in the past 1
             year.

          -  Other criteria apply.
Clinical trial NCT01243775 (phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: belotaxel, belloxa
SMILES: [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Stage IIIB/IV or Relapsed NSCLC

          -  Age >= 18 years

          -  At least one measurable lesion by RECIST (version 1.1)

          -  ECOG PS 0, 1, 2

          -  Hematologic profile

               -  Hgb > 8 g/dL, ANC >= 2,000/m3, Platelet >= 100,000/m3

          -  Hepatic profile

               -  Total bilirubin <= 1.5 x upper normal value

               -  Transaminases <= 3 x upper normal value <= 5 x upper normal value in case of
                  liver metastasis

          -  Creatinine <= 1.5mg/dL

          -  Patients should be recovered from toxicities of previous treatment.

          -  Written informed consent by patient or surrogates

        Exclusion Criteria:

          -  Patients who had been previously treated with chemotherapy for NSCLC

          -  Active infection requiring antibiotics treatment

          -  Prior diagnosis of other malignancy except radically treated basal cell or squamous
             cell carcinoma of the skin and carcinoma in situ of the uterine cervix

          -  Peripheral neuropathy >= grade 2 by NCI CTCAE 4.0

          -  Uncontrolled hypertension, Acute myocardial infarction within 6 months Unstable
             angina, Congestive heart failure >= NYHA grade 2 Uncontrolled significant arrhythmia

          -  Patients who entered other clinical trials within 4 weeks

          -  Pregnant or lactating women. women with child bearing age who are not willing to a
             contraceptive measure
Clinical trial NCT00545454 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: ssr150106, placebos
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Either treatment-naïve patients, or those who have discontinued their Rheumatoid
             Arthritis-directed medication due to intolerability or insufficient efficacy

          -  At least 9 out of 68 tender joints; 6 out of 66 swollen joints; morning stiffness 45
             min

          -  C-Reactive Protein >=1.8 mg/dl confirmed during screening period

          -  Non-poor Cytochrome P2D6 metabolizer status

        Exclusion Criteria:

          -  Functional Rheumatoid Arthritis class IV

          -  Fever

          -  Infections with hepatitis B, or C, or HIV

          -  Presence or history (<5 years) of cancer

          -  Manifest or latent tuberculosis

          -  Functional abnormalities (including laboratory values) judged as clinically relevant

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00599911 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: lu aa24530, duloxetine, placebo
SMILES: CC1=CC=C(SC2=CC=CC=C2C2CCNCC2)C=C1, CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Major Depressive Episode that has lasted at least 3 months

          -  Moderate to severe depression

        Exclusion Criteria:

          -  Any current psychiatric disorder established as the principal diagnosis other than MDD
             as defined in the DSM-IV-TR and as assessed with the Mini-International
             Neuropsychiatric Interview (MINI)

          -  Current or past history of: manic or hypomanic episode, schizophrenia or any other
             psychotic disorder, including major depression with psychotic features, mental
             retardation, organic mental disorders, or mental disorders due to a general medical
             condition as defined in the DSM-IV-TR

          -  Major Depressive Episode that has been unresponsive to two adequate courses of
             antidepressant treatment, each of at least 6 weeks duration

          -  Electroconvulsive therapy within 6 months prior to Baseline

          -  Ongoing formal cognitive or behavioural therapy, systematic psychotherapy, or plans to
             initiate such therapy during the study

          -  Clinically significant unstable illness, for example, hepatic or renal insufficiency,
             or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, infectious,
             neoplastic, or metabolic disturbance

          -  The patient is pregnant or breast-feeding
Clinical trial NCT00415909 (phase 2, status: terminated)
Conditions: chronic myelogenous leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: imatinib mesylate (im), tall-104 cells
SMILES: CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with CML in chronic phase who have failed to achieve or have lost an adequate
             response to IM. For the purpose of this trial this will be defined as a lack of any
             cytogenetic response after 6 months of therapy or lack of major cytogenetic response
             after 12 months of therapy with IM. Patients that have lost their major or complete
             cytogenetic response will also be eligible. Patients who show a sustained increase in
             breakpoint cluster region gene (BCR)-Abelson gene (ABL)/ABL [BCR-ABL/ABL] ratio of >/=
             1-log confirmed in at least two consecutive Polymerase Chain Reaction (PCR) analyses
             (at least one month apart from each other) will also be eligible.

          2. *continued from above: Patients with stable molecular response defined as 2
             consecutive PCR-positive results (no more than 1/2 log improvement) will also be
             eligible. Patients must be taking stable dose of IM for at least 3 months before study
             enrollment, and recovered from all toxicities related to IM, to grade 0-1.

          3. Patients should be in complete or partial hematological remission, including white
             blood count (WBC) </=20 x 10(9)/L, and platelets </= 600 x 10(9)/L.

          4. Eastern Cooperative Oncology Group (ECOG) scale performance status of 2 or less.

          5. Age greater than 18 years of age since disease is extremely rare in younger age
             groups.

          6. Adequate liver (total bilirubin of less than 2 times and aspartate aminotransferase
             (AST) or alanine aminotransferase (ALT) of less than 2 times upper limits of normal),
             and renal function (creatinine of less than 2 times upper limit of normal).

          7. Signed informed consent form.

          8. Negative pregnancy test in women of childbearing age.

          9. Negative hepatitis B and C screening blood tests.

        Exclusion Criteria:

          1. Serious intercurrent medical illnesses or active infections requiring parenteral
             antibiotics that would interfere with the ability of the patient to carry out the
             treatment program.

          2. Female patients who are pregnant or breast-feeding.

          3. Patients taking steroids, or those anticipated to receive steroids during the trial
             therapy.

          4. Prior bone marrow transplant.

          5. Known positivity for human immunodeficiency virus (HIV).
Clinical trial NCT01018758 (phase 2, status: completed)
Conditions: chemotherapy-induced nausea and vomiting, non hodgkin's lymphoma
ICD codes: D61.810
Drugs: palonosetron
SMILES: [H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, >18 years of age;

          -  Histologically or cytologically confirmed aggressive NHL (any stage in accordance with
             the REAL Classification);

          -  Patients candidates to a initial chemotherapy treatment;

          -  ECOG performance status of 0-1;

          -  Scheduled to receive a single intravenous dose of at least one of the moderately
             emetogenic agents (according to the modified Hesketh classification) on Day 1;

          -  Written informed consent;

          -  Female of childbearing potential must be using reliable contraceptive measures;

          -  Acceptable hepatic and renal functions;

          -  Willing and able to complete the patient diary.

        Exclusion Criteria:

          -  Highly emetogenic chemotherapy (containing cisplatin, mechlorethamine, streptozotocin,
             cyclophosphamide >1500 mg/sqm; carmustine; dacarbazine; hexamethylmelamine;
             procarbazine), or single-agent chemotherapy with drugs having low/minimal emetogenic
             potential according to the Hesketh classification);

          -  Diagnosis of Hodgkin's Disease or Leukemia;

          -  Candidates to High-Dose Chemotherapy or Bone Marrow/Peripheral Blood Stem Cells
             Transplantation;

          -  Chemotherapy schedules considering the administration of emetogenic drugs in more than
             two consecutive days;

          -  Have received any investigational drugs within 30 days before study entry;

          -  Have received any drug with potential anti-emetic efficacy (with the exception of
             specific corticosteroids foreseen in the chemotherapy combination) within 24 hours of
             treatment initiation);

          -  Prior treatment with Palonosetron;

          -  Have a seizure disorder requiring anticonvulsant medication unless clinically stable
             and free of seizure activity;

          -  Experienced or ongoing vomiting or nausea from any organic etiology, in the screening
             phase;

          -  Clinical evidence of current or impending bowel obstruction, peritonitis, infection,
             uremia, severe mucositis;

          -  Clinically relevant electrolyte abnormalities;

          -  Have a known hypersensitivity to 5HT3 receptor antagonists;

          -  Radiotherapy within 30 days before chemotherapy administration, or scheduled to
             receive radiotherapy within two weeks after chemotherapy;

          -  Female patients who are pregnant or breast feeding;

          -  Inability to understand or cooperate with the study procedures.